• Target

    £750,000

  • Type

    Equity

  • Close Date

    Feb 28 2019

  • Status

    Live

RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme. Please read FULL risk warning.

Sutrue

Sutrue has created and patented the world’s first intrinsically safe automated suturing device.

A pledge is not a commitment. You will be asked to confirm in the next section.

Track
Contact
Companies
House
Twitter

Overview

Sutrue has created and patented the world’s first intrinsically safe automated suturing devices for both standard and endoscopic wound closure that use industry-standard needles. This revolutionises the process of medical stitching, which hasn’t changed since Ancient Egyptian times. Until now, there has not been a clinically effective solution to needle-safe suturing.

Sutrue devices produce a perfect suture at the touch of a button, with improved speed, accuracy and clinical quality. The enclosed needle, held in a disposable cartridge, answers the unresolved safety issue of needlestick injury (accidental penetration of the skin with a potentially contaminated needle) when suturing in both the medical and veterinary surgical settings, protecting surgeons and ancillary staff during and after surgery.

The Sutrue devices enable healthcare employers to meet their legal obligations. Professional bodies such as the American Nurses Association (ANA) are pressing industry for solutions - “Manufacturers partner with surgeons and surgeon groups to develop suture and scalpel designs that both reduce risk and are comfortable and intuitive for surgeons to use….”

The key elements of the devices are protected by patent. In the UK, USA, Hong Kong, Australia, Russia and Europe patent applications have been granted, to be followed by those already submitted to Brazil, Canada and India.

Suture is seeking investment to finance the production and assembly of several functioning devices, which will then be regulated and employed in both veterinary and human medical evaluations for CE regulation. In addition, it will provide funds to support commercial exploitation and marketing activities

Deal Manager avatar

Deal Manager
Scott Haughton

  • Sector: Healthcare
  • Region: UK: South-East
  • Stage: Pre-revenue, over £200k to £1m invested to date
  • Eligible Tax: EIS
  • Board Requirement: Will consider further board appointments
  • Pre Money Valuation: £15,000,000
  • Share Price: £191.20
  • Originator: Sutrue
This section is currently locked.
Please Sign Up or Log In to unlock.

Team

This section is currently locked.
Please Sign Up or Log In to unlock.

Market

This section is currently locked.
Please Sign Up or Log In to unlock.

Discussions

This section is currently locked.
Please Sign Up or Log In to unlock.

Deal documents

This section is currently locked.
Please Sign Up or Log In to unlock.

Originator


Originator: Sutrue

Deal Type: Equity

Geographical Focus: UK

About: Sutrue has created and patented the world’s first intrinsically safe automated suturing devices for both standard and endoscopic wound closure that use industry-standard needles.

Type: Company raising finance

Contact Name: Nia Dokova

Date established: March 2012

Date Joined Envestry: November 2018